Investing.com — ARS Pharmaceuticals stock saw a significant rise, peaking at an 11% gain, marking the biggest intraday gain since August.
The rise was driven by the company’s announcement of its preliminary fourth-quarter net sales for its allergy spray, Neffy, which beat analysts’ forecasts.
Neffy’s preliminary fourth-quarter net revenue was approximately $6.5 million. That figure far exceeded the average estimate of $3.11 million projected by analysts, according to the Bloomberg survey.
In 2024, total product net sales were approximately $7.1 million. This revenue was generated after the allergy spray became available to wholesalers and pharmacies on September 23.
Looking ahead to 2025, ARS Pharmaceuticals has indicated its intention to drive demand and gain more traction with its target prescribers.
This article was generated with the support of AI and reviewed by an editor. For more information, consult our General Terms and Conditions.
